Non-thermal Plasma Endothelial Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current techniques for accelerating endothelial cell proliferation, such as using exogenous angiogenic growth factors, face challenges in achieving optimal dose, dose gradient, and timing, and often result in tissue damage or require expensive setups.
Innovation Solution
Contacting endothelial cells with non-thermal plasma to release angiogenic growth factors like fibroblast growth factor-2, which induces cell proliferation, using atmospheric pressure dielectric barrier discharge plasma with controlled intensity and duration to promote or inhibit angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If exogenous angiogenic growth factors are added to accelerate endothelial cell proliferation, then cell proliferation is improved, but achieving optimal dose, dose gradient, and timing becomes difficult
Solution Approach 1:
The patent employs endogenous growth factors that are already present within the cells themselves rather than adding external factors. The cells serve their own function of producing and releasing the necessary angiogenic factors, eliminating the need for precise external dosing control while maintaining effective proliferation stimulation
Solution Approach 2:
The patent pre-loads cells with high concentrations of angiogenic growth factors before treatment. This preliminary accumulation within the cells allows for controlled release over time, providing the necessary dose gradient and timing without requiring precise external administration control
2Productivity
If techniques are used to release endogenous angiogenic growth factors from cells, then endothelial cell proliferation is improved, but surrounding tissue and cells are damaged
Solution Approach 1:
The patent replaces mechanical or physical stimulation methods (such as laser, electromagnetic fields, or radiation) with a chemical/biological approach using non-thermal plasma. This substitution releases endogenous growth factors through controlled plasma activation without the tissue-damaging effects of high-energy physical methods
Solution Approach 2:
The patent uses non-thermal plasma with specific parameter control (temperature, power density, exposure time) to activate growth factor release. By maintaining low temperature and controlling plasma parameters, the method achieves effective factor release while avoiding the thermal damage associated with other stimulation techniques
3Productivity
If techniques are used to release endogenous angiogenic growth factors from cells, then endothelial cell proliferation is improved, but extensive and expensive setup is required
Solution Approach 1:
The patent uses non-thermal plasma generation systems that are simpler and more cost-effective than laser, electromagnetic field, or radiation equipment. The plasma setup can be relatively simple and disposable, eliminating the need for extensive and expensive infrastructure while achieving effective growth factor release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively increases endothelial cell populations by at least 50% to 200% without damaging surrounding tissue, offering a controlled and cost-effective approach for treating conditions like diabetic ulcers or cancer by promoting or inhibiting angiogenesis.
Implementation Method 1
contacting an endothelial cell population with a non-thermal plasma to release an angiogenic growth factor
Implementation Method 2
The non-thermal plasma may be an atmospheric pressure dielectric barrier discharge plasma
Implementation Method 3
the endothelial cell may be contacted with a reactive oxygen species produced by the non-thermal plasma
Data Source
AI summary
Aspects of the present invention are related to methods comprising contacting an endothelial cell in an endothelial cell population with a non-thermal plasma to release an angiogenic growth factor. The released angiogenic growth factor may induce endothelial cell proliferation. In certain embodiments, the angiogenic growth factor is fibroblast growth factor-2. Preferably, the non-thermal plasma may be an atmospheric pressure dielectric barrier discharge. Additional aspects of the present invention are directed to methods for treating a disease comprising promoting angiogenesis by contacting an endothelial cell in a endothelial cell population with a non-thermal plasma to release an angiogenic growth factor. The angiogenic growth factor may induce endothelial cell proliferation. Further aspects of the present invention are directed to methods for treating a disease comprising inhibiting angiogenesis by contacting an endothelial cell in a endothelial cell population with a non-thermal plasma to reduce the number of endothelial cells in the population.